For research use only. Not for therapeutic Use.
GDC-0575 dihydrochloride（Cat No.:I019887）is a potent and selective inhibitor of checkpoint kinase 1 (CHK1), a key regulator of the DNA damage response pathway. By inhibiting CHK1, this compound enhances the sensitivity of cancer cells to DNA-damaging agents, such as chemotherapy and radiation therapy. Preclinical studies have demonstrated its potential in overcoming resistance to standard treatments, leading to improved therapeutic outcomes in various malignancies. Ongoing research is focused on evaluating its safety and efficacy in clinical trials, positioning GDC-0575 dihydrochloride as a promising candidate for enhancing cancer treatment strategies.
| Catalog Number | I019887 |
| CAS Number | 1657014-42-0 |
| Molecular Formula | C₁₆H₂₂BrCl₂N₅O |
| Purity | ≥95% |
| Target | Checkpoint Kinase (Chk) |
| IUPAC Name | N-[4-[(3R)-3-aminopiperidin-1-yl]-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide;dihydrochloride |
| InChI | InChI=1S/C16H20BrN5O.2ClH/c17-11-6-19-15-13(14(11)22-5-1-2-10(18)8-22)12(7-20-15)21-16(23)9-3-4-9;;/h6-7,9-10H,1-5,8,18H2,(H,19,20)(H,21,23);2*1H/t10-;;/m1../s1 |
| InChIKey | OYMHZTORKRPOBI-YQFADDPSSA-N |
| SMILES | C1C[C@H](CN(C1)C2=C3C(=CNC3=NC=C2Br)NC(=O)C4CC4)N.Cl.Cl |
| Reference | [1]. Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679.<br>[2]. Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Jun 15;24(12):2901-2912. |
